87 related articles for article (PubMed ID: 15448170)
1. The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
Salama NN; Fasano A; Thakar M; Eddington ND
J Pharmacol Exp Ther; 2005 Jan; 312(1):199-205. PubMed ID: 15448170
[TBL] [Abstract][Full Text] [Related]
2. Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A.
Song KH; Fasano A; Eddington ND
Int J Pharm; 2008 Mar; 351(1-2):8-14. PubMed ID: 17954018
[TBL] [Abstract][Full Text] [Related]
3. The effect of delta G on the transport and oral absorption of macromolecules.
Salama NN; Fasano A; Thakar M; Eddington ND
J Pharm Sci; 2004 May; 93(5):1310-9. PubMed ID: 15067707
[TBL] [Abstract][Full Text] [Related]
4. Tight junction modulation and its relationship to drug delivery.
Salama NN; Eddington ND; Fasano A
Adv Drug Deliv Rev; 2006 Apr; 58(1):15-28. PubMed ID: 16517003
[TBL] [Abstract][Full Text] [Related]
5. Effect of the biologically active fragment of zonula occludens toxin, delta G, on the intestinal paracellular transport and oral absorption of mannitol.
Salama NN; Fasano A; Lu R; Eddington ND
Int J Pharm; 2003 Jan; 251(1-2):113-21. PubMed ID: 12527181
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of brain distribution of anticancer agents using DeltaG, the 12 kDa active fragment of ZOT.
Menon D; Karyekar CS; Fasano A; Lu R; Eddington ND
Int J Pharm; 2005 Dec; 306(1-2):122-31. PubMed ID: 16274945
[TBL] [Abstract][Full Text] [Related]
7. Enhanced nasal absorption of hydrophilic markers after dosing with AT1002, a tight junction modulator.
Song KH; Fasano A; Eddington ND
Eur J Pharm Biopharm; 2008 May; 69(1):231-7. PubMed ID: 18039562
[TBL] [Abstract][Full Text] [Related]
8. Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats.
Merzlikine A; Rotter C; Rago B; Poe J; Christoffersen C; Thomas VH; Troutman M; El-Kattan A
Drug Dev Ind Pharm; 2009 Sep; 35(9):1082-91. PubMed ID: 19294548
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
10. [Advances in study of novel absorption enhancers based on tight junctions].
Kang A; Liang Y; Hao HP; Xie L; Wang GJ
Yao Xue Xue Bao; 2007 Nov; 42(11):1122-8. PubMed ID: 18300465
[TBL] [Abstract][Full Text] [Related]
11. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
Anand BS; Katragadda S; Mitra AK
J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
[TBL] [Abstract][Full Text] [Related]
13. DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents.
Salama NN; Scott KR; Eddington ND
Biopharm Drug Dispos; 2004 Jul; 25(5):227-36. PubMed ID: 15248192
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir.
Choi WS; Im GJ; Kim DK; Kim TK; Jung I; Kim TS; Lee SJ; Lee N; Kim YW; Kim JS; Chang K
Drug Metab Dispos; 2001 Jul; 29(7):945-9. PubMed ID: 11408358
[TBL] [Abstract][Full Text] [Related]
15. Interaction between valproic acid and acyclovir after intravenous and oral administration in a rabbit model.
van Jaarsveld MF; Walubo A; du Plessis JB
Basic Clin Pharmacol Toxicol; 2007 Dec; 101(6):434-40. PubMed ID: 18028106
[TBL] [Abstract][Full Text] [Related]
16. Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat.
Aghazadeh-Habashi A; Ibrahim A; Carran J; Anastassiades T; Jamali F
J Pharm Pharm Sci; 2006; 9(3):359-64. PubMed ID: 17207418
[TBL] [Abstract][Full Text] [Related]
17. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Kakuda TN; Falcon RW
Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
[TBL] [Abstract][Full Text] [Related]
18. The impact of AT1002 on the delivery of ritonavir in the presence of bioadhesive polymer, carrageenan.
Song KH; Eddington ND
Arch Pharm Res; 2012 May; 35(5):937-43. PubMed ID: 22644862
[TBL] [Abstract][Full Text] [Related]
19. Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells.
Thomsen AE; Christensen MS; Bagger MA; Steffansen B
Eur J Pharm Sci; 2004 Dec; 23(4-5):319-25. PubMed ID: 15567284
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of valacyclovir in the adult horse.
Maxwell LK; Bentz BG; Bourne DW; Erkert RS
J Vet Pharmacol Ther; 2008 Aug; 31(4):312-20. PubMed ID: 18638291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
